HLA-C and acute myeloid leukemia: In contrast to CAR-T therapy, T cell receptor (TCR) based strategies for AML can target both surface and intracellular proteins because the TCR recognizes a peptide derived from antigen in any cellular compartment, which is then presented by a major histocompatibility complex (MHC).